American Vanguard Corp: Form 10-Q for the period ended Mar 31, 2016
Filed with the SEC on May 4, 2016 and accepted by EDGAR at May 3, 2016, 20:19 ET.
Management's discussion and analysis
As filed, 30,434 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
FORWARD-LOOKING STATEMENTS/RISK FACTORS:
The Company, from time-to-time, may discuss forward-looking statements including assumptions concerning the Company’s operations, future results and prospects. These forward-looking statements are based on current expectations and are subject to a number of risks, uncertainties and other factors. In connection with the Private Securities Litigation Reform Act of 1995, the Company provides the following cautionary statements identifying important factors which, among other things, could cause the actual results and events to differ materially from those set forth in or implied by the forward-looking statements and related assumptions contained in the entire Report. Such factors include, but are not limited to: product demand and market acceptance risks; the effect of economic conditions; weather conditions; changes in regulatory policy; the impact of competitive products and pricing; changes in foreign exchange rates; product development and commercialization difficulties; capacity and supply constraints or difficulties; availability of capital resources; general business regulations, including taxes and other risks as detailed from time-to-time in the Company’s reports and filings filed with the U.S. Securities and Exchange Commission (the “SEC”). It is not possible to foresee or identify all such factors. For more detailed information, refer to Item 1A., Risk factors and Item 7A., Quantitative and Qualitative Disclosures about Market Risk, in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015.
RESULTS OF OPERATIONS
Quarter Ended March 31:
| Net sales: | 2016 | 2015 | Change |
|---|---|---|---|
| Insecticides | $33,106 | $34,359 | $(1,253) |
| Herbicides/soil fumigants/fungicides | 24,685 | 21,840 | 2,845 |
| Other, including plant growth regulators | 3,277 | 3,322 | (45) |
| Total crop | 61,068 | 59,521 | 1,547 |
| Non-crop | 8,406 | 7,044 | 1,362 |
| $69,474 | $66,565 | $2,909 | |
| Cost of sales: | |||
| Insecticides | $22,199 | $22,603 | $(404) |
| Herbicides/soil fumigants/fungicides | 13,861 | 13,590 | 271 |
| Other, including plant growth regulators | 1,330 | 1,369 | (39) |
| Total crop | 37,390 | 37,562 | (172) |
| Non-crop | 4,581 | 4,353 | 228 |
| $41,971 | $41,915 | $56 | |
| Gross profit: | |||
| Insecticides | $10,907 | $11,756 | $(849) |
| Herbicides/soil fumigants/fungicides | 10,824 | 8,250 | 2,574 |
| Other, including plant growth regulators | 1,947 | 1,953 | (6) |
| Gross profit crop | 23,678 | 21,959 | 1,719 |
| Gross profit non-crop | 3,825 | 2,691 | 1,134 |
| $27,503 | $24,650 | $2,853 | |
| Gross margin crop | 39% | 37% | |
| Gross margin non-crop | 46% | 38% | |
| Total gross margin | 40% | 37% | |
| 2016 | 2015 | Change | |
| Net sales: | |||
| US | $49,985 | $49,222 | $763 |
| International | 19,489 | 17,343 | 2,146 |
| $69,474 | $66,565 | $2,909 |
18
Overall financial performance including net sales and net income for the quarter ended March 31, 2016 improved as compared to the same period in 2015. Our net sales for the period increased 4% to $69,474, as compared to $66,565 for the first quarter of 2015. Net sales for our crop business were up 3%, and net sales for our non-crop products were up 19%. Our international sales were up 12% and ended at $19,489. A more detailed discussion of general market conditions and sales performance by category of products appears below.
Across our crop business, net sales of our insecticides group were down approximately 4% to end at $33,106, as compared to $34,359 during the first quarter of 2015. This result was driven by a combination of factors, relating to domestic corn, peanuts, sugar cane and cotton as well as international markets. The U.S. corn market has been soft for the past three seasons but seems to have stabilized. In the market we experienced a small year-over-year reduction in sales of our corn insecticide SmartChoice, while our primary granular soil insecticide for corn, Aztec, had flat year-over-year sales. Sales of Mocap® and Nemacur® insecticides, which are used primarily outside the U.S. market, were slightly lower than the prior year. Thimet® sales for use in peanuts and sugar cane plantings were somewhat lower in the first quarter of 2016 due to a delay in delivery timing. Partially offsetting the flat to declining performance of insecticides in other markets, our cotton foliar insecticide Bidrin® posted increased sales due to an expected 11% increase in cotton acres planted in 2016 and pest pressure that is likely to exceed the extremely low infestation levels seen last season.
Within the group of herbicides/fungicides/fumigants used in crop applications, net sales for the first quarter of 2016 increased by approximately 13% to $24,685 from $21,840 in the comparable period in 2015. Net sales of our herbicide products rose 63% due primarily to sales of newly acquired products Hyvar, Krovar, and Scepter. Net sales of our post-emergent herbicide Impact® improved by approximately 15%, which is consistent with a stabilizing U.S. corn market plus the benefit of having worked down of channel inventory levels. Further, sales of Dacthal® declined from the prior year due to a delay in supply. Our soil fumigants business also declined from the prior year’s first quarter as a result of wet weather in the Western and Southeast regions, which inhibited or delayed product application.
Net sales of our other products (which include plant growth regulators, molluscicides and tolling activity), were down approximately 1% as compared to the first quarter of 2015. This performance included lower sales of our Metaldehyde granules offset by strong sales of both our Growth Regulator product NAA and our tolling activities.
Our non-crop sales for the first quarter of 2016 ended up 19% at $8,406, as compared to $7,044 for the same period of the prior year. During the quarter, we experienced stronger sales of Orthene and increased demand for our pharmaceutical products. Furthermore, our Envance majority owned subsidiary earned revenues from a third party for the exclusive right for licenses to certain of our natural oil products. This was partially offset by lower quarterly sales of our aerial mosquito adulticide Dibrom®, primarily from timing of customer order placement.
Our international sales ended at $19,489, as compared to $17,343 for the first quarter of the prior year, driven by the addition of our new Hyvar and Krovar herbicides.
Our cost of sales for the first quarter of 2016 was $41,971 or 60% of net sales. This compared to $41,915 or 63% of net sales for 2015. The Company aggregates a number of key variable, semi-variable and fixed cost components within reported cost of sales. During the three month period ended March 31, 2016, raw material purchase prices decreased by approximately 1%. This favorable movement in purchase prices will start to impact the business over the next few quarters as affected inventory turns. As a percentage of sales, raw materials increased about 1% driven by a change in the specific mix of sales this quarter as compared to the same time last year. Our labor and burden costs remained well controlled and were 12% lower in the three months ended March 31, 2016, as compared to the same period of the prior year. Further, our factory activity and associated factory cost recovery increased by 7%, as compared to the first quarter of 2015. These improvements resulted in lower unabsorbed factory overhead costs which amounted to 6% (of sales) in the first quarter of 2016, as compared to 9% in the same quarter of 2015. Overall these improvements added $1,553 to our gross profit performance in the first quarter of 2016, as compared to this time last year.
Operating expenses decreased by $1,471 to $22,873 for the three months ended March 31, 2016, as compared to the same period in 2015. The differences in operating expenses by department are as follows:
| 2016 | 2015 | Change | |
|---|---|---|---|
| Selling | $6,241 | $7,375 | $(1,134) |
| General and administrative | 7,328 | 6,340 | 988 |
| Research, product development and regulatory | 4,457 | 4,837 | (380) |
| Freight, delivery and warehousing | 4,847 | 5,792 | (945) |
| $22,873 | $24,344 | $(1,471) |
- Selling expenses decreased by $1,134 to end at $6,241 for the three months ended March 31, 2016, as compared to the same period of 2015. The main drivers were decreases in advertising expenses and other sales and marketing support services.
- General and administrative expenses increased by $988 to end at $7,328 for the three months ended March 31, 2016, as compared to the same period of 2015. The main drivers were increased legal costs and in addition, higher incentive compensation accruals as a result of improved quarter over quarter financial performance.
- Research, product development costs and regulatory expenses decreased by $380 to end at $4,457 for the three months ended March 31, 2016, as compared to the same period of 2015. The main driver was timing of product development studies, which have started slower in 2016 than in the prior year.
- Freight, delivery and warehousing costs for the three months ended March 31, 2016 were $4,847 or 7.0% of sales as compared to $5,792 or 8.7% of sales for the same period in 2015. This improvement was primarily driven by reduced inventory levels driving lower warehouse costs and the mix of sales, including lower sales of our high volume bulk fumigant products, in comparison to the same period of the prior year.
Interest costs net of capitalized interest, were $541 in the first three months of 2016, as compared to $641 in the same period of 2015. Interest costs are summarized in the following table:
Average Indebtedness and Interest expense
| Q1 2016 Average Debt | Interest Expense | Interest Rate | Q1 2015 Average Debt | Interest Expense | Interest Rate | |
|---|---|---|---|---|---|---|
| Revolving line of credit (average) | $76,227 | $482 | 2.5% | $106,449 | 516 | 2.0% |
| Notes payable | 44 | — | — | 191 | 1 | — |
| Amortization of deferred loan fees | — | 63 | — | — | 106 | — |
| Amortization of other deferred liabilities | — | 10 | — | — | 47 | — |
| Other interest expense | — | — | — | — | 10 | — |
| Capitalized Interest | — | (14) | — | — | (39) | — |
| Total | $76,271 | $541 | 2.8% | $106,640 | $641 | 2.4% |
The Company’s average overall debt for the three months ended March 31, 2016 was $76,271, as compared to $106,640 for the three months ended March 31, 2015. During the quarter, we continued to focus on managing our working capital and controlling our usage of revolving debt. As can be seen from the table above, our effective bank interest rate on our revolving line of credit was 2.5% for the three months ended March 31, 2016, as compared to 2.0% in 2015. This adverse rate change is driven by increases in the Federal Reserve rate which occurred in August 2015. Further, we continue to operate without an interest rate swap in place. The prior interest rate swap expired on December 31, 2014.
Income tax expense increased by $1,352 to end at an expense of $1,060 for the three months ended March 31, 2016, as compared to a benefit of $292 for the comparable period in 2015. The effective tax rate for the quarter was 25.9%, as compared to 87.2% (which was a tax benefit) in the same period of the prior year. The change in effective tax rate is primarily driven by improved year on year financial performance in jurisdictions with higher tax rates.
Furthermore, the effective tax rate for the three months ended March 31, 2016 is based on the projected income for the full year and is subject to ongoing review and adjustment by management.
During the three months ended March 31, 2016 we recognized a loss of $82 on our investment in TyraTech. There was no similar loss during the three months ended March 31, 2015. This reflected the latest information regarding both the actual financial performance for TyraTech for 2015, as well as the forecast for their financial performance for 2016.
Non-controlling interest amounted to a loss of $153 in the three months ended March 31, 2016, as compared to an income of $94 in the same period of the prior year. Non-controlling interest represents the share of net income or loss that is attributable to the minority stockholder of our majority owned subsidiary, Envance.
Our overall net income for the first three months of 2016 was $2,794 or $0.10 per basic and diluted share, as compared to $51 or $0.00 per basic and diluted share in the same quarter of 2015.
LIQUIDITY AND CAPITAL RESOURCES
Net cash generated by operating activities during the three months ended March 31, 2016 amounted to $9,590, as compared to $19,842 in the same period of the prior year. Net income of $2,947, non-cash depreciation, amortization of intangibles and other long term assets and discounted future liabilities generated $5,416, as compared to $5,433 in the prior year. Additionally, stock based compensation of $456 and changes in other assets and liabilities provided net cash inflow of $8,784, as compared to $6,816 being utilized in the same period of 2015.
During the three months ended March 31, 2016, net sales ended up 4% at $69,474, as compared to the same period of 2015. At March 31, 2016 accounts receivable ended up 4%, as compared to the balance as of March 31, 2015. During the first quarter of 2016 the level of accounts receivable increased by $10,202, as compared to December 31, 2015, whereas the level actually decreased in the comparable period of last year. This change is driven by customer decisions related to timing of early pay.
Inventories ended at $144,415, which was an increase of $7,938 in comparison to December 31, 2015. We anticipated this increase which was driven by the arrival of one large annual receipt of inventory for sale during the balance of 2016 and into early 2017. There was no similar shipment last year as we managed through elevated inventories. It should be noted that the Company purchases and holds raw material, intermediate or finished goods inventory from time to time based on a single annual purchase from a single source or supplier, potentially resulting in peaks in the carrying value of the inventory. As of March 31, 2016, we believe our inventories are valued at the lower of cost or market. In comparison, inventories at March 31, 2015 were $22,566 higher at $166,981.
Our deferred revenues decreased as some customers utilized their advance payments for purchases made during the quarter ended March 31, 2016. During the same period of last year we received one advance payment. No such advanced payment was received in the three months ended March 31, 2016.
The Company accrues programs in line with the growing season upon which specific products are targeted. Typically crop products have a growing season that ends on September 30th each year. During the three months ended March 31, 2016, the Company made accruals in the amount of $13,369. Programs are primarily paid out to customers either in the final quarter of the fiscal year or the first quarter of the next fiscal year. During the first three months of 2016, the Company made payments in the amount of $5,738. Payments are not generally significant in the second and third quarters of each fiscal year. During the three months ended March 31, 2015, the Company accrued $12,670 and made payments in the amount of $7,220.
Our prepaid expense and other assets increased by $1,036, which is normal at this part of the financial year. Accounts payable increased by $13,031, as compared to $3,570 during the same period of the prior year. The increase in 2016 accounts payable is substantially driven by the single inventory receipt in the quarter and discussed above.
The Company utilized $3,998 for investing activities during the three months ended March 31, 2016, as compared to $1,522 during the same period of 2015. This is primarily driven by the Company’s decision to make an investment in a Belgian company that develops biological plant protection products that can be used for the control of pests and disease of agricultural crops.
Financing activities utilized $3,253 principally by paying down on the line of credit during the three months ended March 31, 2016, as compared to utilizing $16,084 for the same purpose this time last year. This included a net repayment of $2,600 against our senior credit facility, as compared to $14,400 for the same period last year. Further, the Company utilized $586 upon vesting of shares and exercise of stock options and received $271 from the sale of common stock under its Employee Stock Purchase Plan, as compared to $965 for the same period of last year.
The Company has a revolving line of credit and various notes payable that together constitute the short-term and long-term loan balances shown in the condensed consolidated balance sheets at March 31, 2016 and December 31, 2015. These are summarized in the following table:
| Indebtedness $000’s | March 31, 2016 Long- term | Short- term | Total | December 31, 2015 Long- term | Short- term | Total |
|---|---|---|---|---|---|---|
| Revolving line of credit | $66,400 | $— | $66,400 | $69,000 | $— | $69,000 |
| Deferred loan fees | (637) | — | (637) | (679) | — | (679) |
| Notes payable | — | 37 | 37 | — | 55 | 55 |
| Total indebtedness | $65,763 | $37 | $65,800 | $68,321 | $55 | $68,376 |
The Company has three key covenants to its senior, secured credit facility with its banking syndicate. The covenants are as follows: (1) the Company must maintain its borrowings below a certain consolidated funded debt ratio (taking into account the Company’s twelve month trailing EBITDA), (2) the Company has a limitation on its annual spending on the acquisition of fixed asset capital additions, and (3) the Company must maintain a certain consolidated fixed charge coverage ratio. As of March 31, 2016 the Company met all covenants in that credit facility.
At March 31, 2016, based on its performance against the most restrictive covenants listed above, the Company had the capacity to increase its borrowings by up to $65,373 under the credit facility agreement. This compares to an available borrowing capacity of $22,710 as of March 31, 2015. This improvement in available borrowing capacity arises from improved financial performance (as measured by EBITDA) for the trailing twelve month period and the reduction in borrowings achieved since the end of the first quarter of 2015.
We believe that anticipated cash flow from operations, existing cash balances and available borrowings under our senior credit facility will be sufficient to provide us with liquidity necessary to fund our working capital and cash requirements for the next twelve months.
RECENTLY ISSUED ACCOUNTING GUIDANCE
In March 2016, the FASB issued ASU 2016-09, Compensation – Stock Compensation (Topic 718). The new standard changes the accounting for certain aspects of share-based payments to employees. The standard requires the recognition of the income tax effects of awards in the income statement when the awards vest or are settled, thus eliminating additional paid in capital pools. The standard also allows for the employer to repurchase more of an employee’s shares for tax withholding purposes without triggering liability accounting. Cash paid by an employer when directly withholding shares for tax-withholding purposes should be classified as a financing activity in the statement of cash flows. In addition, the standard allows for a policy election to account for forfeitures as they occur rather than on an estimated basis. The new standard is effective for fiscal years beginning after December 31, 2016 with early adoption permitted. The Company is currently evaluating the impact of our pending adoption of the new standard on our consolidated financial statements.
In March 2016, FASB issued ASU 2016-07, Investments – Equity Method and Joint Ventures. The new standard eliminates the requirement that an investor retrospectively apply equity method accounting when an investment that it had accounted for by another method initially qualifies for the equity method. The guidance requires that an equity method investor add the cost of acquiring the additional interest in the investee to the current basis of the investor’s previously held interest and adopt the equity method of accounting as of the date the investment becomes qualified for equity method accounting. The new standard is effective for fiscal years beginning after December 31, 2016 with early adoption permitted. The Company is currently evaluating the impact of our pending adoption of the new standard on our consolidated financial statements
In February 2016, FASB issued ASU 2016-02, Leases. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the impact of our pending adoption of the new standard on our consolidated financial statements.
In January 2016, FASB issued ASU 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities. The update provides that equity investments with readily determinable values be measured at fair value and changes in the fair value flow through net income. These changes historically have run through other comprehensive income. Equity investments without readily determinable fair values have the option to be measured at fair value or at cost adjusted for changes in observable prices minus impairment. Changes in either method are also recognized in net income. The standard requires a qualitative assessment of impairment indicators at each reporting period. For financial liabilities, entities that elect the fair value option must recognize the change in fair value attributable to instrument-specific credit risk in other comprehensive income rather than net income. Lastly, regarding deferred tax assets, the need for a valuation allowance on a deferred tax asset will need to be assessed related to available-for-sale debt securities. The guidance is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Earlier adoption is permitted. The Company is currently evaluating the impact of our pending adoption of the new standard on our consolidated financial statements.
In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes. The standard requires all deferred tax assets and liabilities, as well as any related valuation allowance, to be classified as non-current on the balance sheet. The guidance is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years and earlier adoption is permitted. The Company is currently evaluating the impact of our pending adoption of the new standard on our consolidated financial statements.
In July 2015, FASB issued ASU 2015-11, Inventory (Topic 330). Topic 330 currently requires an entity to measure inventory at the lower of cost or market, where market could be replacement cost, net realizable value, or net realizable value less an approximately normal profit margin. This ASU limits the scope to inventory that is measured using first-in, first-out (FIFO) or average cost and requires inventory be measured at the lower of costs or net realizable value. The new standard is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The Company will evaluate the impact of this adoption for fiscal year 2017.
In August 2014, FASB issued ASU 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. This ASU requires that management of an entity assesses whether there is substantial doubt about the ability of the entity to continue as a going concern and for making the appropriate disclosures. The assessment must be performed at each annual and interim reporting period, and there is substantial doubt about an entity’s ability to continue as a going concern if it is probable that the entity will be unable to meet its obligations as they become due within 12 months of the date of the financial statements are issued. In the assessment, management must consider the information available at the date of issuance of the financial statements, as well as mitigating factors and plans to alleviate the substantial doubt. ASU 2014-15 is effective for annual period ending after December 15, 2016 and interim periods thereafter. Early application is permitted. Upon adoption, the Company will follow the guidance in this ASU when assessing going concern.
In June 2014, FASB issued ASU 2014-12, Compensation—Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period, a consensus of the FASB Emerging Issues Task Force. ASU 2014-12 requires that a performance target that affects vesting of share-based payment awards and that could be achieved after the requisite service period be treated as a performance condition. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the periods for which the requisite service has already been rendered. If the performance target becomes probable of being achieved before the end of the requisite service period, the remaining unrecognized compensation cost should be recognized prospectively over the remaining requisite service period. The total amount of compensation cost recognized during and after the requisite service period should reflect the number of awards that are expected to vest and should be adjusted to reflect those awards that ultimately vest. The requisite service period ends when the employee can cease rendering service and still be eligible to vest in the award if the performance target is achieved. ASU 2014-12 is effective for all entities for interim and annual periods beginning after December 15, 2015, with early adoption permitted. An entity may apply the amendments in ASU 2014-12 either (i) prospectively to all awards granted or modified after the effective date or (ii) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. The adoption of ASU 2014-12 is not expected to have a material impact on the Company’s consolidated financial condition or results of operations. The Company adopted this ASU for interim and annual periods of 2015.
In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers. ASU 2014-09 outlines a new, single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. This new revenue recognition model provides a five-step analysis in determining when and how revenue is recognized. The new model will require revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services. In March 2016, the FASB issued an amendment to the standard, ASU 2016-08, to clarify the implementation guidance on principal versus agent considerations. Under the amendment, an entity is required to determine whether the nature of its promise is to provide the specified good or service itself (that is, the entity is a principal) or to arrange for that good or service to be provided by the other party (that is, the entity is an agent). In April 2016, the FASB issued another amendment to the standard, ASU 2016-10, to clarify identifying performance obligations and the licensing implementation guidance, which retaining the related principles for those areas. The standard and the amendments are effective for annual periods beginning after December 15, 2016, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). We are currently evaluating the impact of our pending adoption of ASU 2014-09 on our consolidated financial statements and have not yet determined the method by which we will adopt the standard in 2017 or its impact on our consolidated financial statements.
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
The Company continually re-assesses the critical accounting policies used in preparing its financial statements. In the Company’s Form 10-K filed with the SEC for the year ended December 31, 2015, the Company provided a comprehensive statement of critical accounting policies. These policies have been reviewed in detail as part of the preparation work for this Form 10-Q. After our review of these matters, we have determined that, during the subject reporting period, there has been no material change to the critical accounting policies that are listed in the Company’s Form 10-K for the year ended December 31, 2015.
Market risk
As filed, 1,252 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The Company is exposed to market risk related to changes in interest rates, primarily from its borrowing activities. The Company’s indebtedness to its primary lender is evidenced by a line of credit with a variable rate of interest, which fluctuates with changes in the lender’s reference rate. For more information, please refer to the applicable disclosures in the Company’s Form 10-K filed with the SEC for the year ended December 31, 2015.
The Company conducts business in various foreign currencies, primarily in Europe, Mexico, Central and South America. Therefore changes in the value of the currencies of such countries or regions affect the Company’s financial position and cash flows when translated into U.S. Dollars. The Company has mitigated and will continue to mitigate a portion of its currency exchange exposure through natural hedges based on the operation of decentralized foreign operating companies in which the majority of all costs are local-currency based. Furthermore, the Company has established a procedure for covering forward exchange rates on specific purchase orders when appropriate. A 10% change in the value of all foreign currencies would have an immaterial effect on the Company’s financial position and cash flows.
Controls and procedures
As filed, 1,057 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
As of March 31, 2016, the Company has a comprehensive set of disclosure controls and procedures designed to ensure that all information required to be disclosed in our filings under the Securities Exchange Act (1934) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. As of March 31, 2016, the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer has concluded, based on their evaluation, that the Company’s disclosure controls and procedures are effective to provide reasonable assurance of the achievement of the objectives described above.
There were no changes in the Company’s internal controls over financial reporting that occurred during the most recent quarter that have materially affected, or are reasonably likely to materially affect, the Company’s internal controls over financial reporting.
PART II. OTHER INFORMATION
The Company was not required to report any matters or changes for any items of Part II except as disclosed below.
Risk factors
As filed, 406 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The Company continually re-assesses the business risks, and as part of that process detailed a range of risk factors in the disclosures in American Vanguard’s Report on Form 10-K for the fiscal year ended December 31, 2015, filed on March 2, 2016. In preparing this document, we have reviewed all the risk factors included in that document and find that there are no material changes to those risk factors.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2016-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2016-01-01 to 2016-03-31 | $69.5m | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months2016-01-01 to 2016-03-31 | $42.0m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2016-01-01 to 2016-03-31 | $27.5m | us-gaap:GrossProfit |
| Operating income | 3 months2016-01-01 to 2016-03-31 | $4.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2016-01-01 to 2016-03-31 | $541.0k | us-gaap:InterestExpense |
| Income tax | 3 months2016-01-01 to 2016-03-31 | $1.1m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2016-01-01 to 2016-03-31 | $2.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2016-01-01 to 2016-03-31 | $0.10 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2016-01-01 to 2016-03-31 | $0.10 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2016-01-01 to 2016-03-31 | 29,307,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2016-01-01 to 2016-03-31 | $9.6m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Cash and equivalents | At period end2016-03-31 | $7.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2016-03-31 | $258.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2016-03-31 | $463.5m | us-gaap:Assets |
| Current liabilities | At period end2016-03-31 | $95.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2016-03-31 | $192.0m | us-gaap:Liabilities |
| Long-term debt | At period end2016-03-31 | $65.8m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2016-03-31 | $37.0k | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2016-03-31 | $271.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001193125-16-575509. Last ingested by Listed: Nov 11, 2026, 00:16 ET. Listed shows no prices and gives no investment advice.